Escient
is a California-based biotechnology company that researches and develops novel therapeutics for the treatment of neurosensory-inflammatory disorders... Read moreEscient
is a California-based biotechnology company that researches and develops novel therapeutics for the treatment of neurosensory-inflammatory disorders... Read more
News
Apr 23, 2024
The Business Journals: Philadelphia
Escient: Incyte to acquire San Diego pharma firm in $750 million deal
Apr 23, 2024
Benzinga
Escient: Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Nov 28, 2023
Business Wire
Press Release: Escient : Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis
Oct 11, 2023
Acrofan
Escient: Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria
Jun 22, 2023
Pharmabiz
Escient: Escient Pharma announces positive results from phase 1 study of EP262 to treat mast cell mediated disorders
Jun 08, 2023
FinanzNachrichten
Escient: Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in Inhibition of Mast Cell Degranulation in Multiple Species at the European Academy of Allergy and Clinical Immunology
Feb 26, 2023
Life Care News
Escient: Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Pharmacology of EP262 at the American Academy of Allergy, Asthma and Immunology Annual Meeting
Jan 30, 2023
Picante Today
Escient: Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
Dec 07, 2022
FinanzNachrichten
Escient: Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum
Dec 02, 2022
The San Diego Union Tribune
Escient: San Diego biotech Escient Pharmaceuticals pulls in $120M to pursue novel drug candidates
Escient Competitors
1
2
3
4
5
6
7
8
9
10